Commentary: Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C - Authors' reply

1. Talal AH, Lafleur J, Hoop R, et al. Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients. Aliment Pharmacol Ther 2013; 37: 473–81. 2. Lettmeier B, M€ uhlberger N, Schwarzer R, et al. Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol 2008; 49: 528–36. 3. Sarrazin C, H ezode C, Zeuzem S, et al. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56(Suppl. 1): S88–100. 4. Aghemo A, Lampertico P, Colombo M. Assessing long-term treatment efficacy in chronic hepatitis B and C: between evidence and common sense. J Hepatol 2012; 57: 1326–35. 5. Volk ML, Tocco R, Saini S, et al. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009; 50: 1750–5. 6. Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513–21.